BIOMARKERS & IMMUNO US: In-Person

6th Annual Biomarkers & Precision Medicine USA Congress 4th Annual Advances in Immuno-Oncology USA Congress

03 - 04 October 2022 | San Diego, USA

300+

LEADING PHARMA, BIOTECH AND ACADEMIC DELEGATES 60+

PRESENTATIONS, CASE STUDIES AND DISCUSSIONS 9

INTERACTIVE TRACKS ON THE LATEST INNOVATIONS

Conference Brochure

KEY SPEAKERS INCLUDE



Ken Chang Daiichi Sankyo



Mehran Moghaddam OROX Biosciences, Inc.



Ewa Carrier Fibrogen



Jadwiga Bienkowska **Pfizer**





Jeffrey Wallin Kelly Shanahan Gilead Sciences Inc Living with Metastatic Breast Cancer



More Information: <u>Biomarkers US</u> | <u>Immuno US</u> Join the Conversation: <u>#BiomarkersSeries22</u> | <u>#IMMUNOSeries22</u>

BROCHURE CONTENTS

- **04.** Who is Attending?
- 05. Sponsors
- **06.** Session Topic Areas
- **07.** Confirmed Speakers
- 09. Full Programme Agenda
- **18.** Networking Dinner & Drinks
- **19.** Venue Information
- 20. Forthcoming Events



With the co-located Biomarkers and Immuno US Conference coming up soon, I am very excited to reveal what we have in store for you during our interactive & engaging conference.

This conference will unite senior-level experts to provide a focussed forum for thought-provoking discussion and to gain insights from the key figures in the community. This year's comprehensive programme will enable you to gain a forward-looking perspective on the latest technologies and strategies impacting biomarker research, alongside in-depth considerations of advancing Immuno-Oncology drug development.

This year's Biomarkers & Precision Medicine programme will enable you to benefit from updates on utilising biomarkers for translational science, diagnostics and clinical development. Further sessions provide insights into topical technology innovation in this space, from the latest imaging tools and AI strategies through to genomic technologies for precision medicine.

Our Immuno-Oncology programme will provide case studies on a variety of key therapeutic modalities, including cell therapies, combination strategies and novel antibodies. Alongside this, there will be discussion on advancing preclinical models and developing effective biomarker strategies. As a new area of focus, the agenda will include sessions on targeting the tumour microenvironment through spatial biology, imaging and pathology

This packed conference will provide this cutting-edge content through presentations, panel discussions and speaker Q&As.

We are hugely thankful to our speakers, who have given their time to deliver interesting, thought-provoking presentations, and to our sponsoring companies, who have worked closely with us to provide you with unique opportunities to access the latest information on solutions and services that can directly impact and improve your research

WELCOME

and results. Without their support this event would not be possible, so please do take some time to visit them on-site, but also their featured sponsor pages on the accompanying event app and engage with the content and resources that they have made available.

Networking & knowledge-sharing is at the heart of what we do. Apart from the innovative programme, your event experience will be linked to the Swapcard event app, where you can engage in a variety of event features including AI-based suggestions to make connections, creating a personalised conference agenda, chat through text or video and the ability to access peer to peer networking. The event platform will allow you to exchange contact details, files and links freely to build a wealth of information for your use, post-event. To get the most out of the conference, the accompanying platform will be open 7-days before the start of the conference.

To maximise your access to available resources at the event we have created the Digital Gallery, on the digital platform where you can find a host of product information or informative content most relevant to you and your research interests.

If you have any questions, please contact a member of the team on-site and we will be available to assist and ensure you get the best experience you can from the event.

We look forward to welcoming you to the conference. See you then!

Hayley Watson,

Senior Director, Commercial Strategy

On-site Health & Safety

At Oxford Global, the safety and well-being of our clients is our top priority, and we are committed to ensuring that our congresses remain safe and successful.

For more information, please see <u>www.oxfordglobal.co.uk/biomarkers-series-us/plan-your-visit/</u>

WHO IS ATTENDING?

300+ VPs, Directors & Senior Managers will be attending, coming from leading healthcare, biotech, pharma and research institutions in the following fields and more:

- Biomarker Discovery
- Translational Science
- Clinical Development
- Assay Development
- Genomic Markers
- Diagnostics

- Personalised Medicine
- Biomarker Technologies
- Immuno-Oncology
- Cancer Immunology
- Oncology Biomarkers
- Cell & Gene Therapy
- Translational Immunology
- Preclinical & Clinical Oncology
- Combination Therapy
- Antibody Development
- Biomarker Verification



Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Assay Kits & Platforms
- Biomarker Verification
- Companion Diagnostics
- Protein Biomarkers
- Clinical Research & Trial
 Development
- Genomic Technologies
- Imaging Tools
- Liquid Biopsy
- Plexing Platforms
- Immunoassays

- Data Management
- Biomarker Discovery &
 Development
- Digitalisation & Digital Technologies
- Molecular & Digital Pathology



www.oxfordglobal.co.uk/biomarkers-series-us/sponsorship/

SESSION TOPIC AREAS

Biomarkers & Immuno US: In-Person features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 60** industry insights, sponsored presentations, think tank roundtable discussions and followed by digital access to on-demand content delivered through our **online event platform**.

DAY ONE - 03 OCTOBER 2022

Track 1.1: Biomarkers in Drug Discovery & Translational Science

- Case studies in biomarker validation in: Neuroscience, Rare diseases, Immunology, Oncology & Cardiovascular disorders
- Qualification of biomarkers for translational studies
- Efficacy and PK/PD biomarkers in drug development

Track 1.2: Biomarkers for Precision Medicine & Diagnostic Development

- Diagnostic Development: Companion, Tissue & PoC
- Enabling personalised medicine & demonstrating clinical utility
- Case studies in targeted therapies for oncology
- Biospecimens for qualification and validation for precision medicine

Track 2: Biomarkers for Clinical Development

- Transforming clinical development through biomarker driven clinical trial design
- Use of molecular biomarkers in clinical trials
- Overcoming challenges of clinical validation & translation
- Case studies in the optimization of trial design

Track 3: Discovery & Development: Cell Therapies & Antibody Approaches

- Traditional Cell Therapies - T-Cells and NK Cells
- Non-Conventional Cell Therapies -Macrophages and TCRs
- Latest antibodybased approaches, including bispecifics

Track 4: Biomarkers & Precision Medicine in Immuno-Oncology

- Novel biomarkers in the Immuno-Oncology research
- Improving patient responses through biomarker development
- Diagnostic tools within I-O, including liquid biopsies for precise treatments

DAY TWO - 04 OCTOBER 2022

Track 1: Biomarker Analysis & Emerging Technologies

- Big data analytics and sampling techniques
- Imaging technologies, CNS imaging techniques & digital pathology
- Multiplexing technologies, Flow cytometry & Mass spectrometry
- Digital Pathology Tools & Technologies

Track 2: Genomic Markers For Precision Medicine & Clinical Research

- Case studies in CTCs
- Importance of liquid biopsies for precision medicine in oncology
- Using NGS and Single Cell Genomic Technologies in Clinical Development
- Understanding genetic variants as the basis of disease

Track 3: Discovery & Development: Intra-tumoral Immunotherapies & Combination Strategies

- Oncolytic and non-oncology viruses & agonists
- Delivering intra-tumoral immunotherapies for solid tumours
- Rational of different combinations, including combination of IO agents as well as radiotherapy & chemotherapy

Track 4: Translational & Preclinical Development

- Assay development, including pharmacodynamic assays
- Translating animal models
- into human and clinicallyrelevant models for screening therapies
- Safety & toxicity considerations
- Application of spatial biology tools in the tumor microenvironment

CONFIRMED SPEAKERS – DAY ONE



NICOLE BJORKLUND Director, Translational Research & Development, Cohen Veterans

Bioscience



SIMONE FILOSTO Director, Cell Biology, Translational Medicine, Kite Pharma



EWA CARRIER Vice President, Clinical Development, Fibrogen



ALEKHYA POCHIRAJU Product Development, Global Operations Manager, Genentech



MICHELLE GRAHAM Principal Research Scientist, AbbVie



CHRISTIE FANTON Vice President, Translational Medicine, Nektar Therapeutics



GRAHAM JONES Head of Research and Innovation, Novartis





MIKE DAMORE Director, Translational Oncology Lead, Pfizer



SIMI AHMED Senior Vice President, Strategic Partnerships, NYSCF



YOUG THAKER Principal Scientist, Sorrento Therapeutics



JADWIGA BIENKOWSKA Senior Director, Computational Biology ORD, Pfizer



BONNIE HAMMER Senior Vice President, Research & Development, Invenra, Inc.



KOUSTUBH RANADE Head of Translational Medicine, Immunocore



AUDE-HELENE CAPIETTO

Senior Principal Scientific Researcher, Cancer Immunology Department, Genentech



ANDREW ALLEN Co-Founder, President and Chief Executive Officer, Gritstone bio



BYUNG HA LEE Senior Vice President & Chief Scientific Officer, NeoImmuneTech



NADIA HASSOUNAH Principal Scientist, Translational Immuno-Oncology, Novartis



MICHAEL GROANING Global Medical Affairs Lead Genitourinary, Amgen



CONRAD MESSAM Senior Director, Merck



KATIE NEWHALL Vice President Translational Clinical Development, Cellectis







ANDERS DAMHOLT Head of Clinical Development -Human Health, Chr. Hansen



DAVE HOON Professor, Director, St. John's Cancer Institute



VILMA DECMAN Senior Director, Head of the Cellular Biomarkers, GSK



CONFIRMED SPEAKERS – DAY TWO



KELLY SHANAHAN Advocate, Living With Metastatic



IEFFREY WALLIN Executive Director, Biomarker

Breast Cancer

Sciences, Gilead Sciences Inc



HONG LIN

Head of Clinical Immunology/Flow Cytometry, Stony Brook University School of Medicine



KEN CHANG

Director, Clinical Biomarkers, Daiichi Sankyo



MICHAEL ROEHRL Professor of Pathology, Lab Medicine, Cell & Developmental Biology, Memorial Sloan Kettering Cancer Center



ANAND GIDDABASAPPA Head of Global Science and Technology, Comparative Medicine, Pfizer



SEAN XIE Director, Drug Safety Research & Development, Pfizer



KATHERINE CALL Former Senior Director, Biomarkers, Sanofi



CHIH-LIANG CHIN Executive Director, Biomarker & Target Sciences, Merck & Co., Inc.



IOHN LU Chief Executive Officer, Hebecell Corporation



RUSSELL LAMONTAGNE

President and Chief Executive Officer, LaMontagne Gallery



IOHN ROSSI Vice President, Head of Translational Medicine, Syncopation Life Sciences



PHILIP ARLEN President and Chief Executive Officer,



TAUSEEF BUTT President and Chief Executive Officer.

Precision Biologics, Inc

LifeSensors Inc



PRAVIN KAUMAYA Professor of Medicine and Director Vaccine Development, The Ohio State University



KENNETH RAMOS Executive Director, Texas A&M Institute of Biosciences and Technology



SETH CROSBY Director, Research Collaborations, Washington University



GIULIO PACIOTTI Chief Science Officer, Cytimmune Sciences, Inc.



LILING WARREN tevo Senior Director, Head of Translational Statistics, Teva Pharmaceuticals



MEHRAN MOGHADDAM Chief Executive Officer, OROX BioSciences, Inc.



DIANA PRICE Executive Director, Biosciences, Neuropore Therapeutics, Inc.



SRIPAD RAM Pfizer Digital Pathology and Image Analysis Group Lead, Pfizer

SARA FERNANDO-MARTINEZ





AMANDA KLEIN Executive Director, Transplant Therapeutics Consortium, Critical Path Institute

For more information on our speakers, please read the biographies available on our **event app** \rightarrow



DAY ONE: 03 OCTOBER 2022

08:20

09:50

Ø

Oxford Global Welcome Address & Chairperson's Opening Address

Opening Keynote Address: Discovery Of Biomarkers For Immuno-Oncology Therapies

- Identification of clinical biomarkers for Phase 1 from analysis of single cell sequencing in preclinical models and patient samples
- Clinical Biomarker development of response from phase 3 clinical trials with analysis multi omics data with applications of machine learning
 - Discovery of mechanism of resistance to IO therapies to inform new targets and combinations

JADWIGA BIENKOWSKA, Senior Director, Computational Biology ORD, Pfizer

	ROOM 1: BIOMARKERS IN DRUG DISCOVERY & TRANSLATIONAL SCIENCE	ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT	ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: CELL THERAPIES & ANTIBODY THERAPIES	ROOM 4: BIOMARKERS & PRECISION MEDICINE IN IMMUNO-ONCOLOGY
	Track Chair: NICOLE BJORKLUND, Director, Translational Research & Development, Cohen Veterans Bioscience	Track Chair: KATIE NEWHALL, Vice President of Translational Clinical Development, Cellectis	Track Chair: NADIA HASSOUNAH, Principal Scientist, Translational Immuno-Oncology, Novartis	Track Chair: MICHAEL GROANING, Global Medical Affairs Lead Genitourinary, Amgen
08:55	Fast-Tracking Precision Diagnostics And Tailored Therapeutics For Post-Traumatic Stress Disorder & Traumatic Brain Injury	Harnessing NK And T Cells Against Cancer Through IL-15 Pathway Activation	Preclinical Data Of An Anti-CD3/Anti-ROR1 Bispecific-Armed Oncolytic Virus	Biomarkers In The Era Of Immuno-Oncology
	 CVB has built critical infrastructure to support the building of multi-modal mechanistic disease models including resources such as biobanking, analytics pipelines, data sharing platform, and an assay evaluation paradigm A case-study will be presented with results and takeaway lessons 	 Understanding preclinical and clinical MOA Discussing early clinical results of NKTR-255 	 Sorrento's modified oncolytic viruses (OV) platform expressing an αCD3/αROR1 tandem scFv bispecific (bsAb) αCD3/αROR1 specifically binds to ROR1-expressing tumor cells and CD3+ T cells triggering strong T cell activation αCD3/αROR1 BsAb showed strong and specific tumor killing activity 	 Exploratory RNA expression signature analysis Pan-tumor TMB analysis for Pembrolizumab Monotherapies Exploring Cancer Genetic Events and Pembrolizumab Efficacy Combination Therapies and Exploratory Biomarkers Emerging Technologies: ctDNA
	NICOLE BJORKLUND, Director, Translational Research & Development, Cohen Veterans Bioscience	CHRISTIE FANTON, Vice President, Translational Medicine, Nektar Therapeutics	YOUG THAKER, Principal Scientist, Sorrento Therapeutics	E.J. DETTMAN, Principal Scientist, Clinical Research, Merck
	Solution Provider Presentation	Enabling Biomarker-Driven Clinical Trials	State Of The Nation In Cell & Gene Therapy: Navigating The Journeys Within The Journey	Spatial Characterization Of The Tumor Microenvironments Using Multiplexed Ion Beam Imaging (MIBI)
09:20	Solution Provider Presentation	 Enabling Biomarker-Driven Clinical Trials Collaborative models for biomarker research Overcoming barriers to implementing biomarker strategies Facilitating transition of biomarkers from discovery to development 		Microenvironments Using Multiplexed Ion
09:20	Solution Provider Presentation Senior Representative, Volition	 Collaborative models for biomarker research Overcoming barriers to implementing biomarker strategies Facilitating transition of biomarkers from discovery to 	 Navigating The Journeys Within The Journey Current cell and gene therapy program development and manufacturing scenarios Program bottlenecks which can derail timelines and how to mitigate them Considerations of an end-to-end integrated CGT portfolio versus a more fragmented approach Glimpse into how the field continues to evolve for 	 Microenvironments Using Multiplexed Ion Beam Imaging (MIBI) How MIBI technology has enabled deep spatial immunophenotyping of diseased tissue sections How spatial organization of innate and adaptive immune cell subsets, tumor cells, and structural tissue features were identified with MIBI How MIBI revealed systems level differences in progressive
09:20	Senior Representative,	 Collaborative models for biomarker research Overcoming barriers to implementing biomarker strategies Facilitating transition of biomarkers from discovery to development PATRICK HURBAN, Vice President – Translational Genomics & General Manager, Translational Science & Innovation Laboratory,	 Navigating The Journeys Within The Journey Current cell and gene therapy program development and manufacturing scenarios Program bottlenecks which can derail timelines and how to mitigate them Considerations of an end-to-end integrated CGT portfolio versus a more fragmented approach Glimpse into how the field continues to evolve for regulatory, manufacturing, analytics (QA/QC) KAREN DOUCETTE, Cell and Gene Therapy Navigator, 	 Microenvironments Using Multiplexed Ion Beam Imaging (MIBI) How MIBI technology has enabled deep spatial immunophenotyping of diseased tissue sections How spatial organization of innate and adaptive immune cell subsets, tumor cells, and structural tissue features were identified with MIBI How MIBI revealed systems level differences in progressive disease versus treatment-responsive patient groups SAM KIMMEY, Field Applications Scientist,

Morning Break & 1-2-1 Meetings x4

ROOM 1: BIOMARKERS FOR PRECISION MEDICINE & DIAGNOSTIC DEVELOPMENT

Seven Habits Of Highly Effective Biomarkers

ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT

Precision Medicine In Practice For NSCLC

- · Next generation biomarkers: from omics to precision medicine
- Integration of bioinformatics and database-driven approaches
- Importance of machine learning in biomarker discovery cycle
- 11:10
- VOLODIMIR OLEXIOUK, Team Lead AI and Analytics, BioLizard



Precision Medicine Strategies In Clinical Trials - The Importance Of Diversity In Biomarker Research

11:40

(Joining Online) ALEKHYA POCHIRAJU, Product Development, Global Operations Manager, Genentech

Panel Discussion: Biomarkers For Clinical **Development & Precision Medicine**

- Developing future precision medicine strategies
- Precision medicine tools to transform patient care · Challenges of integrating precision medicine in clinical
- development

12:05

Moderator: MIKE DAMORE, Director, Translational Oncology Lead, Pfizer

Panellists:

GREGORY FRANK, Director, Business Development, ImaginAb KENNETH RAMOS, Executive Director, Texas A&M

Institute of Biosciences and Technology LILING WARREN, Senior Director, Head of Translational Statistics. Teva Pharmaceuticals

- Over the past decade, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) has become reliant on tissue specimens and biomarkers to help guide
- targeted treatment options • By testing a tumor sample for biomarkers, investigators can learn if a cancer has one of these defects, which may point
- to a specific treatment choice There are now many biomarker-defined patient subgroups. with evidence showing that treatment with targeted therapies has superior clinical outcomes when compared with cytotoxic agents. However, rapid change in the field of precision medicine brings with it the challenge of translating biomarker recommendations into clinical practice and clinical development
- · Herein, we will discuss the application of practice guidelines to patients with NSCLC. We will also review novel diagnostic assays, such as Next Generation Sequencing (NGS) and simplex / multiplex immunohistochemistry (IHC) in lung tissue specimens within Cerba Research offerings

RANIA GASPO, Global Therapy Area Expert / Oncology, Cerba Research



Translational Biomarkers To Guide Clinical Development For Allogeneic CAR T Cell Therapies

• Translational clinical assays are designed to inform the product characteristics, patient factors, dose, safety, and target strategies for a given allogeneic CAR T-cell therapy

 Harmonization of assays and integrated data sets are part of a multipronged approach to translational development that is critical to the success of our current and future therapies

KATIE NEWHALL, Vice President of Translational Clinical Development, Cellectis

Candidate Biomarkers For Pancreatic Cancer -Experience From Clinical Studies

CTGF as prognostic biomarker in PDAC

Fibrogen

- Ca 19.9 as candidate predictive biomarker in LAPC
- FDG-PET as candidate predictive biomarker in LAPC

EWA CARRIER, Vice President, Clinical Development, Development. Invenra Inc.

BONNIE HAMMER, Senior Vice President, Research &

The Building Blocks Of Antibody Registration

And Data Management In CDD Vault

leading researchers

consumer goods companies

antibodies will be shown

Collaborative Drug Discovery

Therapies

therapy

Genentech

peripheral nerves

to peripheral neurons

CDD provides a modern approach to drug discovery

research informatics trusted globally by thousands of

The CDD Vault is a hosted biological and chemical database

manage, analyze, and present data for biotech companies.

CROs, academic labs, research hospitals, agrochemical and

register all different types of entities; examples of registered

JANICE DARLINGTON, Customer Engagement Scientist,

Advances In Neoantigen Characterization

For The Development Of Neoantigen-Specific

· Improving neoantigen selection for neoantigen-targeted

· Determining new strategy to improve anti-tumor efficacy

AUDE-HELENE CAPIETTO, Senior Principal Scientific

Preclinical Development Of A Bispecific

Antibody For Neuroblastoma With Improved

• A standard of care antibody treatment for neuroblastoma

causes dose limiting pain due to expression of the target on

· Invenra has used their bispecific antibody platform to more

specifically target the neuroblastoma cells and avoid binding

to tumor rejection in preclinical models

Researcher, Cancer Immunology,

Efficacy And Reduced Pain

Characterizing neoantigen-specific T cell responses leading

CDD, VAULT

Complexity Simplified

management system that helps project teams securely

• CDD Vault a is a flexible, configurable system used to

ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: **ROOM 4: BIOMARKERS & PRECISION CELL THERAPIES & ANTIBODY THERAPIES** MEDICINE IN IMMUNO-ONCOLOGY

Receptor Occupancy Assays To Improve Dose Selection And Pharmacologic Monitoring

- · Immunotherapy employs the use of antibodies that target
- receptors on immune cell subsets and alter their functions • Assays that assess the binding (receptor occupancy) and the biologic effect of a therapeutic are necessary as part of the drug development continuum
- Prior to receptor occupancy (RO) assay development, it is critical to understand the therapeutic mechanism of action (MoA) and reagent availability to ensure a well-defined, reproducible assav
- Optimization and validation of a RO assay will greatly improve dose selection and drug effectiveness in clinical trial settings

LISA JENNINGS, Managing Executive US, Chief Scientific Officer, Trial Facility Manager, MLM Medical Labs



Circulating Tumor DNA May Be A Better Surrogate Of Overall Survival Than RECIST **Response In Uveal Melanoma Patients Treated With Tebentafusp**


(Joining Online) KOUSTUBH RANADE, Head of Translational Medicine, Immunocore

ctDNA Quantitation As A Superior Biomarker **Of Efficacy For Immunotherapy In Cancer Compared To Radiology/RECIST**

- Cancer immunotherapy drives T cell infiltration into tumors Measuring lesion size on CT scan is of uncertain value given that lesion size is a balance of tumor cell destruction and T cell proliferation
- Longitudinal quantitation of ctDNA may provide superior information versus RECIST

ANDREW ALLEN, Co-Founder, President and Chief Executive Officer. Gritstone bio





16:00

ROOM 1: BIOMARKERS IN DRUG DISCOVERY & TRANSLATIONAL SCIENCE

Enhancing Biomarker Discovery In Neurodegenerative Diseases Using Advances In Mass Spectrometry-Based Proteomics

- Biognosys is a world leader in next generation, unbiased mass spectrometry-based proteomics
- Workflows are matrix agnostic and can be used for biomarker discovery in tissues, cells and biofluids including CSF and plasma
- Peptide-centric analysis provides insights beyond protein expression
- Novel workflows significantly improve protein identification depth and confidence
- Age is the primary risk factor for neurodegeneration and cognitive decline
- · Both CSF and plasma profiling enable robust protein biomarker identification that correlate strongly with age (R2 > 0.87)
- 17.20
- Additional biomarkers, including subset panels, can be further exploited to predict cognitive decline
- In this way, mass spectrometry-based proteomics can be used to identify novel biomarkers that can be used for age and disease prediction with a view towards early identification and treatment options

NIGEL BEATON, Scientific Director, Discovery Proteomics, Biognosys



Panel Discussion: Harmonising Biomarker **Discovery & Validation Efforts**

• Harmonising biomarker discovery through academia/

- pharmaceutical collaboration
- Ensuring reproducibility

17:50

Moderator: SIMI AHMED, Senior Vice President, Strategic Partnerships, NYSCF

Panellists:

JOHN ROSSI, Vice President, Head of Translational Medicine, Syncopation Life Sciences NICOLE BJORKLUND, Director, Translational Sciences, **Cohen Veterans Bioscience** VILMA DECMAN, Senior Director, Head of the Cellular Biomarkers, GSK

Passive Monitoring Using Composite Measures

· Passive, composite digital measures offer high potential for early stage disease detection

• To be effective for longitudinal analysis, user-friendly (low friction) devices are essential

(Joining Online) GRAHAM JONES, Head of Research and Innovation, Novartis

ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT

Dismantling Barriers To Biomarker Testing

- Precision medicine is among the key contributors in progressing cancer survivorship
- However, utilization of biomarker testing, critical to enabling precision medicine treatments, is below guideline recommendations
- The presentation will discuss these barriers and suggest tangible and sustainable solutions that can be done to overcome them – such as equitable access to biomarker testing, standardized care approaches, and biomarker testing education among providers and patients

Diagnostics, US Medical Affairs, Oncology, AstraZeneca



Biomarkers Associated With Response And Toxicity To CAR-T Cell Intervention In 2nd Line Large B Cell Lymphoma

- Chimeric Antigen Receptor (CAR) T cell therapy at Kite • Positive outcome of ZUMA-7, the first-ever phase 3 randomized study of Axi-Cel Vs Standard of Care in 2nd line
- Large B cell Lymphoma Association of outcome with Pharmacokinetics (PK), Pharmacodynamics (PD), Tumor Biology and Product features

SIMONE FILOSTO, Director, Cell Biology, Translational Medicine. **Kite Pharma**

Probiotic, Bif195, Alleviates Intestinal Damage Caused By Intake Of NSAIDs: Understand The **Mode Of Action Through Biomarker Analysis**

 Strategy of biomarker analysis • Possible Bif195 mode of action · Safety and benefits of Bif195 in relation in to of intake NSAIDs

(Joining Online) ANDERS DAMHOLT, Head of Clinical Development - Human Health, Chr. Hansen

BYUNG HA LEE, Senior Vice President & Chief Scientific Officer. NeoImmuneTech

Delegates are invited to attend the co-located sessions

MICHAEL GROANING, Global Medical Affairs Lead Genitourinary, Amgen

Translation And Biomarker Analysis In Clinical Trials: Operational Considerations

- · Identify the operational challenges for global registrational studies
- · Regulatory challenges to consider
- Critical challenges with sample tracking

18:40

18:15

CONRAD MESSAM, Senior Director, Merck

(Joining Online) OMAR PEREZ, Head of Medical



ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY:

• TCR-LA combine the TCR-recognition mode with therapeutic

• TCR-LA are mAbs that recognize and bind to peptide/HLA

Immunitrack has a high throughput platform for epitope

of MHC/epitope complexes (NeoScreen platform). With

cancer testis antigens and of cancer driver mutations

TCR-LA characterization platform (AbScreen)

discovery by conducting affinity and stability assessments

this technology we have identified immunogenic targets of

Immunitrack has implemented and validated a first-in-class

CELL THERAPIES & ANTIBODY THERAPIES

Targeting Intracellular Tumor Antigens

efficacy of conventional mAbs

complexes on the tumor cell surface

New Avenues For Treating Cancer: TCR-LA

Developing A Translational Strategy For A T

• Understanding the MoA: science-based biomarker strategy

- Location vs convenience: tissue vs peripheral biomarkers
- Continuous improvement in the search for a breakthrough

STEPHAN THORGRIMSEN, Chief Executive Officer, Immunitrack

Imaging Biomarkers In Patient Selection



Cell Pipeline

End of Day One & Drinks Reception




ROOM 4: BIOMARKERS & PRECISION

Delegates are invited to attend the co-located sessions

MEDICINE IN IMMUNO-ONCOLOGY



	DAY TWO: 04 OCTOBER 2022				
	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES		ROOM 3: DISCOVERY & DEVELOPMENT: INTRA-TUMORAL IMMUNOTHERAPIES & COMBINATION STRATEGIES		
	Track Chair: LILING WARREN, Senior Director, Head of Translational Statistics, Teva Pharmaceuticals		Track Chair: MEHRAN MOGHADDAM, Chief Executive Officer, OROX Biosciences, Inc.		
09:00	 Track Keynote Address: Dual Toll-Like Receptor 2 And 9 Antagonists For The Treatment Of Neurodegenerative Diseases Toll-Like Receptors (TLRs) regulate immune responses to molecular patterns and are implicated in neurodegeneration Neuropore has discovered novel small molecule dual TLR2/TLR9 inhibitors that improve disease-relevant endpoints in animal models of ALS and Parkinson's disease DIANA PRICE, Executive Director, Biosciences, Neuropore Therapeutics, Inc. 		 Track Keynote Address: Discovery And Development Of Bifunctional Small Molecules With Novel MOA In Oncology OROX is dedicated to discovery of drugs for oncology, inflammatory, and fibrotic diseases Our platform technology yields bifunctional small-molecules capable of immunomodulation with exceptional efficacy in preclinical models OROX is seeking VC investments and strategic alliance MEHRAN MOGHADDAM, Chief Executive Officer, OROX Biosciences, Inc. 		
	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES	ROOM 2: GENOMIC MARKERS FOR PRECISION MEDICINE & CLINICAL RESEARCH	ROOM 3: DISCOVERY & DEVELOPMENT: INTRA-TUMORAL IMMUNOTHERAPIES & COMBINATION STRATEGIES	ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY	
	Track Chair: LILING WARREN, Senior Director, Head of Translational Statistics, Teva Pharmaceuticals	Track Chair: KENNETH RAMOS, Executive Director, Texas A&M Institute of Biosciences and Technology	Track Chair: MEHRAN MOGHADDAM, Chief Executive Officer, OROX Biosciences, Inc.	Track Chair: JOHN ROSSI, Vice President, Head of Translational Medicine, Syncopation Life Sciences	
	Al-Based Digital Pathology For NASH	Effect Of Co-Mutations & FLT3-ITD Variant Allele Frequency (VAF) On Response To Quizartinib Or Salvage Chemotherapy (SC) In Relapsed/ Refractory (R/R) Acute Myeloid Leukemia (AML)	Novel PROTAC Drugs: Unique Membrane Ubiquitin Ligase That Degrades RTK And Membrane Proteins	Functional Characterization Of Chimeric Engulfment Receptor (CER) T Cells For The Treatment Of Hematologic And Solid Malignancies	
09:25	 Biomarkers for the development of NASH therapeutics Use AI-based digital pathology to interrogate the disease biology of NASH Enable AI-based digital pathology as an aiding tool to improve NASH clinical trials 	 The effect of baseline co-mutations in a trial of R/R AML patients with FLT3-ITD mutations treated with quizartinib were evaluated Key co-mutations identified were found to potentially impact treatment response and OS with quizartinib, relative to SC 	 Current PROTAC drugs utilize Cereblon, VHL, HDM2, clAPs, others ubiquitin ligases that degrade a limited set of intracellular proteins. Progenra has discovered a unique membrane ubiquitin ligase that is remarkably efficient in degrading membrane proteins and receptor tyrosine kinases 	 Development of a single autologous engineered T cell product for use across multiple cancer indications Novel CER T-cell products leveraging naturally occurring phagocytic receptors represent a new class of cell therapy products targeting "tumor stress ligands" Engulfment and enhanced APC-like function of CER-based products are hypothesized to overcome heterogeneous disease through recruitment of endogenous adaptive and innate anti-tumor immune response 	
	CHIH-LIANG CHIN, Executive Director, Biomarker & Target Sciences, Merck & Co., Inc.	KEN CHANG, Director, Clinical Biomarkers, Daiichi Sankyo	TAUSEEF BUTT, President and Chief Executive Officer, LifeSensors Inc	JOHN ROSSI, Vice President, Head of Translational Medicine, Syncopation Life Sciences	
09:50	Multiplexed Tools To Spatially Address The Immune Composition Of The Tumor Microenvironment	Solution Provider Presentation		Bioassays To Support Development And Characterization Of New Drugs In Immuno- Oncology	
	 How a high-throughput, high-plex (up to 12-plex) staining and mIF assay development can more accurately predict treatment response How whole-slide image analysis of the tumor microenvironment, can provide insight into specific cancer 			 Much of that revolution in immuno-oncology has been fueled by the clinical success of immune checkpoint inhibitors, targeting cytokines, antibody dependent cell cytotoxicity and complement dependent cytotoxicity via the T cell activation 	
	 How advanced Al-driven image analysis can be applied to discover cell types, populations and morphological context Application case studies 		Delegates are invited to attend the co-located sessions	 Reaction biology has established state-of-art high throughput screening procedures for measuring the ability of new Biologics or compounds to activate T cells All of our screening procedures and experimental methods will help to identify new therapeutic biologics or compounds for drug discovery in immune-oncology field 	
	BONNIE PHILLIPS, Global FAS Manager, Ultivue	Senior Representative, Personalis		MOHAMMAD HAQUE, Senior scientist II, Reaction Biology	
	Ultivue	🎲 Personalis [®]		BIOLOGY	





	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES	ROOM 2: GENOMIC MARKERS FOR PRECISION MEDICINE & CLINICAL RESEARCH	ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY		
	Machine Learning In Imaging Biomarker Development	Liquid Biopsy Of LINE-1 Analytes For Early Detection Of Lung Disease	Targeting The Tumour Microenvironment For More Effective And Efficient Cancer Immunotherapy		
12:45	<i>(Joining Online)</i> SEAN XIE, Director, Drug Safety Research & Development, Pfizer	 Aberrant activation of the oncogenic retrotransposon, LINE-1, is a hallmark of lung disease Measurements of LINE-1 can be used as a "liquid biopsy' of lung pathology The LINE-1 cargo in extracellular vesicles mirrors the levels in the cells of origin and influenced by sex and ethnicity KENNETH RAMOS, Executive Director, Texas A&M Institute of Biosciences and Technology 	(Joining Online) KOUSTUBH RANADE, Head of Translational Medicine, Immunocore		
13:10	Lunch Break & 1-2-1 Meetings x3				
	Panel Discussion: Novel Techniques & The New Age Of Biomarkers	Clonal Amplification Of Peripheral B And T Cells Is Associated With Clinical Response To Checkpoint Blockade In Chronic Hepatitis B	Preclinical/Clinical Development Of A Neo-Epitope Targeted Monoclonal Antibody For Cancer Therapy		
14:20	 Biomarker identification and qualification Matching technology to biomarker context of use and requirements Utility and challenges of multiple biomarkers Leveraging public data and evaluating biomarkers in additional diseases Moderator: KATHERINE CALL, Former Senior Director,	 Introduction to single cell sequencing and uses in clinical trials Example of the use of single cell sequencing in a clinical trial with anti-PD1 Leveraging single cell data from blood and tissue samples 	 Antibody/target identification Mechanisms of action (MOA): ADCC and others Clinical Trial Development based on MOA 		
	Sanofi Panellists: SARA FERRANDO-MARTINEZ, Principal Scientist; Head of Clinical Sciences, Neolmmune Tech (<i>joining Online</i>) AMANDA KLEIN, Executive Director, Transplant Therapeutics Consortium, Critical Path Institute MICHELLE GRAHAM, Principal Research Scientist, AbbVie	JEFFREY WALLIN, Executive Director, Biomarker Sciences, Gilead Sciences Inc	PHILIP ARLEN, President and Chief Executive Officer, Precision Biologics, Inc		
	ROOM 1: BIOMARKER ANALYSIS & EMERGING T	ECHNOLOGIES	ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY		
14:45	 Novel Method For The Generation And Analysis Of Microbiome Data MVRSION uses high throughput microfluidics to generate amplicons out of 1000's of reactions at once Analysis uses an initial alignment which yields bacterial species that MAY be present Computational filtering results in SPECIES-level calls and abundance 		Workshop: Advances In Combination Therapies Presentation: Combination Approaches To Solid Tumours • Gold Nanoparticle-Based-Tumor-Targeting Nanomedicines • TNF • Paclitaxel • Immuno-Oncology		
	SETH CROSBY, Director, Research Collaborations, Washington University		Cytokine combinations GIULIO PACIOTTI, Chief Science Officer, Cytimmune Sciences, Inc.		
15:10	Afternoon Break				
	 Challenges And Opportunities In Translational Data Analytics ML in biomarker 'omics analysis (e.g. to support patient selection) Deep learning in translational research Statistical considerations when translating predictive biomarkers from discovery to clinical development LILING WARREN, Senior Director, Head of Translational Statistics, Teva Pharmaceuticals 		Workshop (cont'd.): Advances In Combination Therapies Panel Discussion: Approach From Clinic To Approval		
15:35			Expectations of regulatory perspectives		
			Moderator: RUSSELL LAMONTAGNE, President and Chief Executive Officer, LaMontagne Gallery Panellists: GIULIO PACIOTTI, Chief Science Officer, Cytimmune Sciences, Inc. PRAVIN KAUMAYA, Professor of Medicine and Director Vaccine Development, The Ohio State University		
	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES				
	Flow Cytometry Tools For Advanced Biomarker Analysis				

16:00



TRACK 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES

A Patient Perspective On The Importance Of Biomarker Testing In Cancer Diagnosis - Is It Prime Time Yet? Patients Are Impatient Awaiting The Promise Of Precision Medicine

• You don't need a crystal ball to know patients need predictive biomarkers


16:25 • Does NGS stand for Not Good, Sorry if there aren't any treatments to match mutations?

Smash the silos: sharing data saves lives

(Joining Online) KELLY SHANAHAN, Advocate, Living With Metastatic Breast Cancer

16:50

Closing Networking & End Of Conference




VENUE INFORMATION



DoubleTree by Hilton San Diego — MISSION VALLEY —

7450 Hazard Center Drive, San Diego, California, 92108, USA

Visit Website







DoubleTree by Hilton San Diego - Mission Valley 7450 Hazard Center Drive, San Diego, California, 92108, USA Tel: +1-619-297-5466

DoubleTree by Hilton San Diego - Mission Valley puts you in the center of San Diego. Mission Valley hotel is conveniently located next to the trolley stop, which offers easy transportation to a variety of the city's top attractions including Old Town, Little Italy, Petco Park, San Diego Convention Center, Gaslamp Quarter, and San Diego State University. It is easily accessible by rail, trolly, car, and air.

Detailed travel directions can be found at: www.oxfordglobal.co.uk/immuno-series-us/ plan-your-visit/

Also known as 'America's Finest City', San Diego is home to Balboa Park, the largest urban cultural park in the U.S., that features 15 museums, numerous art galleries, beautiful gardens, the Tony Award-winning The Globe Theaters and the world-famous San Diego Zoo.

FORTHCOMING EVENTS

BIOMARKERS SERIES ACROSS 2022

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations. Covering Biomarkers, Genomic Markers, Digital Biomarkers, CTCs & Liquid Biopsies, Flow Cytometry & Multiplex Tools and more.



Biomarkers UK: In-Person 03 - 04 May 2022 | London, UK

Biomarkers US: In-Person 03 - 04 October 2022 | San Diego, USA

Biomarkers Analysis Europe: In-Person 01 - 02 November 2022 | Berlin, Germany

Biomarkers for NASH Symposium 07 December 2022 | Online: GMT (UTC+0)



Members of our Biomarkers Series Community have access to all these events. <u>Please click here</u> for more information.

Biologics Series

Proteins & Antibodies | Peptides & Oligonucleotides | Antibody Engineering Vaccines

Cell Series

Cell Culture & Bioprocessing | Cell Therapy Analytics | Cell & Gene Therapy Manufacturing Advanced Therapy Development

Discovery Series

Organ Modelling | Drug Discovery Neuroscience Discovery | Discovery Chemistry

Formulation & Delivery Series

Formulation & Drug Delivery Inhalation & Respiratory Drug Delivery RNA Therapeutics & Delivery Pharmaceutical Lyophilisation Blood-Brain Barrier

Immuno Series

Advances in Immuno-Oncology Autoimmunity & Immunology Tumor Microenvironment Preclinical Immuno-Oncology

NextGen Omics Series

Next Gen Sequencing | Single Cell Analysis Genome Editing | Digital PCR | Spatial Biology Single Cell Proteomics

NetZero Series

Sustainability in Pharma & Healthcare

PharmaTec Series

Pharmaceutical IT | SmartLabs & Laboratory Informatics Pharmaceutical Mobile Robotics Digital Medicine

Visit <u>www.oxfordglobal.co.uk/calendar/</u> to explore our diverse portfolio of events across 2022.



Visit our Biomarkers Portal

Bringing you the latest research in Biomarkers, Genomic Markers, Clinical & Translational Biomarkers & Biomarker Analysis through a range of Interviews, Industry Insights & Expert Opinions

www.oxfordglobal.co.uk/biomarkers/